The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $7.29

Today's change+0.18 +2.53%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $7.29

Today's change+0.18 +2.53%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

ARIAD Pharmaceuticals Inc up sharply

ARIAD Pharmaceuticals Inc closed up sharply Wednesday, rallying (U.S.)$0.18 or 2.53% to (U.S.)$7.29. Over the last five days, shares have gained 18.73% and 6.89% year to date. Shares have outperformed the S&P 500 by 41.07% during the last year.

Key company metrics

  • Open(U.S.) $7.07
  • Previous close(U.S.) $7.11
  • High(U.S.) $7.35
  • Low(U.S.) $7.03
  • Bid / Ask-- / --
  • YTD % change+6.89%
  • Volume5,188,699
  • Average volume (10-day)6,606,188
  • Average volume (1-month)6,025,013
  • Average volume (3-month)6,387,785
  • 52-week range(U.S.) $3.80 to (U.S.) $9.83
  • Beta1.41
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.24
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-492.24%

ARIAD Pharmaceuticals Inc has a net profit margin of -492.24%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.77%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1512128
Total other revenue--------
Total revenue1512128
Gross profit1410100
Total cost of revenue1219
Total operating expense62686182
Selling / general / administrative34343238
Research & development28322936
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-47-56-50-74
Interest income (expense), net non-operating-4-100
Gain (loss) on sale of assets--------
Other--------
Income before tax-50-57-50-74
Income after tax-50-57-50-74
Income tax, total0000
Net income-50-57-50-74
Total adjustments to net income--------
Net income before extra. items-50-57-50-74
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-50-57-50-74
Inc. avail. to common incl. extra. items-50-57-50-74
Diluted net income-50-57-50-74
Dilution adjustment0000
Diluted weighted average shares187187186186
Diluted EPS excluding extraordinary itemsvalue per share-0.27-0.30-0.27-0.40
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.27-0.30-0.27-0.40